Phase 1, First-in-human, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses of XEN1101 and Preliminary Open-label Pharmacodynamic Assessment in Healthy Subjects

Trial Profile

Phase 1, First-in-human, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses of XEN1101 and Preliminary Open-label Pharmacodynamic Assessment in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2018

At a glance

  • Drugs XEN 1101 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; First in man
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2018 According to a Xenon Pharmaceuticals media release, the company plans to publish the complete XEN1101 phase 1 clinical trial results at a scientific meeting.
    • 07 Aug 2018 Status changed from recruiting to active, no longer recruiting, according to a Xenon Pharmaceuticals media release.
    • 27 Jun 2018 Planned End Date changed from 1 Apr 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top